Latest Breaking News On - Healthcare communications - Page 6 : comparemela.com

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months.

United statesUniversity of pennsylvaniaMark formanMadeline nafusMike beyerWilliam chouUniversity of pennsylvania gene therapy programHealthcare communicationsExchange commissionUpenn gene therapy programSam brown incPassage bio incPassage bioGene therapyPrivate securities litigation reform actRisk factors

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN And Updated Strategic Priorities

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN And Updated Strategic Priorities
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of pennsylvaniaMadeline nafusMark formanWilliam chouMike beyerSam brown incExchange commissionPassage bio incUpenn gene therapy programUniversity of pennsylvania gene therapy programHealthcare communicationsPassage bioGene therapyPrivate securities litigation reform actRisk factors

Patrick Baffuto of Hybrid Healthcare Joins the International Advisory Committee for the 20th International Congress on Infectious Diseases (ICID)

Patrick Baffuto of Hybrid Healthcare Joins the International Advisory Committee for the 20th International Congress on Infectious Diseases (ICID)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cape townWestern capeSouth africaJani hegartyPatrick baffutoInternational congress on infectious diseaseAffairs pharmaceutical companyClient services of hybrid healthcare communicationsHealth wellness partnersInternational advisory committeeProgramme committeeHealthcare communicationsExecutive vice president client servicesHybrid healthcare communicationsInternational congressInfectious disease

PR News | BPD Acquires Revive - Mon , Dec 4, 2023

Revive, which became part of Weber Shandwick in 2016, has been formally acquired by BPD.

Jason brownBoca ratonChris bevotoWeber shandwickWindrose health investorsWeber shandwickHealthcare prHealthcare communicationsChris bevoto

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced.

United statesUniversity of pennsylvaniaStuart hendersonMike beyerHealthcare communicationsSam brown incUniversity of pennsylvania gene therapy programPassage bio incNasdaq listing rulePassage bioInducement optionsGene therapy programBio investorsBio media